What does Tacrolimus Extended-Release Capsules (Astagraf Xl) do in plain English—and how does it work inside your body?
Tacrolimus Extended-Release Capsules is an FDA-regulated Calcineurin Inhibitor Immunosuppressant (RxNorm RxCUI RXN-714322003-2432). Mechanistically, Delivered via 5 mg/1 Capsule, Coated, Extended Release and 1 mg/1 Capsule, Coated, Extended Release (oral-route; NDC 71432-2003, 0469-0677), Tacrolimus Extended-Release Capsules mediates calcineurin inhibitor immunosuppressant physiological effects manufactured/labeled by Chengdu Suncadia Medicine Co., Ltd. with dose-dependent receptor occupancy and systemic clearance. [1][2].
When your doctor writes a prescription for Tacrolimus Extended-Release Capsules (RxNorm RxCUI RXN-714322003-2432, also dispensed under brand names including Astagraf Xl), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Delivered via 5 mg/1 Capsule, Coated, Extended Release and 1 mg/1 Capsule, Coated, Extended Release (oral-route; NDC 71432-2003, 0469-0677), Tacrolimus Extended-Release Capsules mediates calcineurin inhibitor immunosuppressant physiological effects manufactured/labeled by Chengdu Suncadia Medicine Co., Ltd. with dose-dependent receptor occupancy and systemic clearance. [2].
Across real-world patient logs on dotMD (87% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Tacrolimus Extended-Release Capsules tablet bottle and confirm with your pharmacist that it matches your prescribed strength (5 mg/1 Capsule, Coated, Extended Release, 1 mg/1 Capsule, Coated, Extended Release, .5 mg/1 Capsule, Coated, Extended Release).